It’s small consolation to someone facing retribution at work for their boss’ indiscretion, but if nothing else your question ...

Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L ...

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful ...

When cells can’t destroy damaged proteins, a hidden backup system led by NRF1 steps in to prevent toxic buildup.

Detailed price information for Rakovina Therapeutics Inc (RKV-X) from The Globe and Mail including charting and trades.

Incidence of venous thromboembolism remains 'substantial' despite expert guidelines and newer risk prediction scores ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- ...

Eating healthy does not directly equate to you getting all the nutrients your body needs. Your metabolism, digestion, and the intricate dance of enzymes in the gut are influenced by lifestyle habits ...